Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation

Table 1 Comparison of the demographic and clinicopathological data of hepatitis B virus-related hepatocellular carcinoma patients after living donor liver transplantation and deceased donor liver transplantation

Variables	LDLT	DDLT	P value
	(n = 84)	(n = 276)	(2-tailed)
Gender (F/M)	6/78	29/247	0.36
Age-yr (mean)	44.3	47.3	0.06
Age, yr (< 60/≥ 60)	79/5	238/38	0.05
BMI (< 24/24-27/≥ 27)	57/19/8	185/65/26	0.98
Child-Pugh (A/B/C)	43/34/7	137/119/20	0.89
Meld score ( ≤ 10/10-20/> 21)	47/33/2	150/92/19	0.25
AFP (μg/L) (< 400/≥ 400)	37/43	141/135	0.45
Preoperative	17/67	101/175	0.0051
adjuvant therapy (Y/N)
Tumor No. ( ≤ 3/> 3)	62/18	206/50	0.56
Largest Tumor Size	40/24/16	128/65/73	0.35
( ≤ 5/5-9/> 9)-cm
Total tumor size	28/21/31	77/41/91	0.46
( ≤ 5/5-9/> 9)-cm
Vascular invasion (Y/N)	20/64	97/179	0.05
Milan criteria (Y/N)	22/58	69/199	0.75
UCSF criteria (Y/N)	28/52	84/184	0.54
Hangzhou criteria (Y/N)	39/41	112/145	0.42
HBV-DNA-copies/ml	32/52	76/131	0.83
(< 1.00E + 03/> 1.00E + 03)
Differentiation (1-2/3-4)	32/11	114/70	0.13

¹Significant P value. UCSF: University of California, San Francisco; HBV: Hepatitis B virus; LDLT: Living donor liver transplantation; DDLT: Deceased donor liver transplantation; BMI: Body mass index; AFP: α-fetoprotein.